A Phase I Clinical Trial of FWD1802 in Patients With ER+/HER2- BC.

Status Recruiting

Clinical Trial Summary

This is a phase I open-label dose escalation trial of FWD1802 as monotherapy and in combination with palbociclib in patients with ER+/HER2- unresectable locally advanced or metastatic breast cancer The goal of this clinical trial] is to learn about in ER+/HER2- BC participant population. The main questions it aims to answer are: - Establish the recommended phase II dose (RP2D) and/or the maximum tolerated dose (MTD) of FWD1802 as monotherapy and in combination with palbociclib in patients with ER+/HER2- unresectable locally advanced or metastatic breast cancer. - Explore the safety and tolerability of FWD1802 as monotherapy and in combination with Palbociclib. - Characterise Pharmacokinetics of FWD1802 as monotherapy and in combination with palbociclib. - Explore preliminary efficacy signals.

Clinical Trial Description

This is a multiple cohort study, an initial dose escalation phase is designed to confirm the safe dose of FWD1802 as monotherapy and in combination with Palbociclib. A Safety Monitoring Committee (SMC) will monitor the safety, tolerability, and PK data during this phase. Once ascertained, an expansion cohort will be opened to explore the efficacy of FWD1802 as monotherapy and in combination with Palbociclib. Part A is an open-label, dose escalation of FWD 1802 as monotherapy . Dose escalation steps will be determined by the Safety Monitoring Committee (SMC), based on 3+3 rule except for the accelerated escalation on the 1st dose level. With pharmacokinetic (PK), pharmacodynamics (PD), efficacy and safety data, SMC will evaluate to guide determination of potentially effective dose for part B and C. Part B is an open-label, dose escalation of FWD 1802 in combination with palbociclib fixed dose. Dose escalation steps will be determined by SMC, based on 3+3 rule. With PK, PD, efficacy and safety data, SMC will evaluate to guide determination of potentially effective combination dose. Part C is an open label , dose expansion of FWD 1802 monotherapy on patients with ER+/HER2-/ESR1 mutation, no more than 2 dose levels will be evaluated, with 30 patients at the most in either dose level cohort. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06064812
Study type	Interventional
Source	Forward Pharmaceuticals Co., Ltd.
Contact	Huan Liu
Phone	18911297402
Email	liuh@forward-pharm.con
Status	Recruiting
Phase	Phase 1
Start date	September 12, 2023
Completion date	February 2026

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT04872608` - A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer	Phase 1
Terminated	`NCT02202746` - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer	Phase 2
Completed	`NCT02506556` - Phosphatidylinositol 3-kinase (PI3K) Alpha iNhibition In Advanced Breast Cancer	Phase 2
Recruiting	`NCT05534438` - A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer	Phase 2
Recruiting	`NCT03368729` - Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer	Phase 1/Phase 2
Completed	`NCT04103853` - Safety, Tolerability, and Pharmacokinetics of Proxalutamide Therapy in Women With Metastatic Breast Cancer	Phase 1
Terminated	`NCT01847599` - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib	N/A
Active, not recruiting	`NCT03147287` - Palbociclib After CDK and Endocrine Therapy (PACE)	Phase 2
Not yet recruiting	`NCT06062498` - Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer	Phase 2
Recruiting	`NCT05383196` - Onvansertib + Paclitaxel In TNBC	Phase 1/Phase 2
Recruiting	`NCT04095390` - A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer	Phase 2
Active, not recruiting	`NCT04432454` - Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation	Phase 2
Recruiting	`NCT03323346` - Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer	Phase 2
Recruiting	`NCT05744375` - Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab	Phase 2
Completed	`NCT02924883` - A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy	Phase 2
Completed	`NCT01942135` - Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)	Phase 3
Completed	`NCT01881230` - Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)	Phase 2/Phase 3
Active, not recruiting	`NCT04448886` - Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC	Phase 2
Completed	`NCT01401959` - Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy	Phase 2
Terminated	`NCT04720664` - Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer	Phase 2